Our main accomplishments during the previous funding cycle relevant to the present application are: 1. Identification of new endocannabinoid (EC)-like compounds in the central nervous system, their synthesis and evaluation in various biological settings; 2. Characterization of a neuroprotective role for the EC system in traumatic brain injury (TBI). 3. Defining a role for the EC system in the regulation of skeletal metabolism. Based on our findings we hypothesize that the ECs, EC-like compounds and the cannabinoid receptors have differential and distinct pathophysiologic roles, both after TBI and in maintaining bone remodeling at balance. We propose to test this hypothesis using an array of newly synthesized EC-like compounds (i.e., fatty acid ethanolamides, fatty acid glyceryl esters and fatty acid amides), test their binding to cannabinoid receptors and define their pharmacological actions (by Dr. Mechoulam). This will be followed by identification of corresponding endogenous materials in the brain (by Dr. Mechoulam) and testing their effects in a mouse model for TBI and their role in neurogenesis (by Dr. Shohami) and on the skeleton (by Dr. Bab). These compounds will be also assessed in other biological models available to the PPG such as Dr. Martin's models for pain and reward (Project 1). To further map the role of EC system components in post-TBI recovery and bone remodeling we will analyze TBI-triggered processes (Dr. Shohami) and bone metabolism (Dr. Bab) in mice with conditional deletion of EC genes in the brain and in the skeleton. Some of these mice will be generated by Dr. Cravatt (Project 3) or provided by our collaborators Dr. Zimmer and Dr. Lutz. In a complementary strategy, we will test the post-TBI and skeletal effects of inhibitors of enzymes involved in EC synthesis and degradation (from Drs. Razdan and Cravatt) and of cannabinoid receptor agonists and antagonists (from Drs. Razdan and Mechoulam). Mapping the activity of the EC-like compounds and each of the EC system components is proposed with the objective of identifying molecular drug targets for the benefit of TBI victims, patients with neurodegenerative diseases and sufferers of skeletal deficits resulting from trauma and osteoporosis. Such mapping will probably contribute to the general understanding of the EC system and hence, drug dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA009789-16
Application #
8410113
Study Section
Special Emphasis Panel (ZDA1-RXL-E)
Project Start
Project End
2014-08-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
16
Fiscal Year
2013
Total Cost
$134,351
Indirect Cost
$23,196
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Yun, Bogeon; Lee, HeeJung; Ghosh, Moumita et al. (2014) Serine hydrolase inhibitors block necrotic cell death by preventing calcium overload of the mitochondria and permeability transition pore formation. J Biol Chem 289:1491-504
Galdino, Giovane; Romero, Thiago; Silva, José Felippe Pinho da et al. (2014) Acute resistance exercise induces antinociception by activation of the endocannabinoid system in rats. Anesth Analg 119:702-15
Pertwee, Roger G (2014) Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc Nutr Soc 73:96-105
Vallée, Monique; Vitiello, Sergio; Bellocchio, Luigi et al. (2014) Pregnenolone can protect the brain from cannabis intoxication. Science 343:94-8
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-407
Abdulnour, Joseph; Yasari, Siham; Rabasa-Lhoret, Remi et al. (2014) Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. Obesity (Silver Spring) 22:211-6
Grim, Travis W; Ghosh, Sudeshna; Hsu, Ku-Lung et al. (2014) Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models. Pharmacol Biochem Behav 124:405-11
Wiley, Jenny L; Walentiny, D Matthew; Wright Jr, M Jerry et al. (2014) Endocannabinoid contribution to ?9-tetrahydrocannabinol discrimination in rodents. Eur J Pharmacol 737:97-105
Schlosburg, Joel E; Kinsey, Steven G; Ignatowska-Jankowska, Bogna et al. (2014) Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice. J Pharmacol Exp Ther 350:196-204
Murase, Ryuichi; Kawamura, Rumi; Singer, Eric et al. (2014) Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol 171:4464-77

Showing the most recent 10 out of 231 publications